Literature DB >> 9236680

Decreased survival in patients with co-existent rheumatoid arthritis and bronchiectasis.

D R Swinson1, D Symmons, U Suresh, M Jones, J Booth.   

Abstract

The aim was to compare the 5 yr survival in patients with rheumatoid arthritis (RA) alone, bronchiectasis (Br) alone and RA plus Br (RA-Br). A case-control study was carried out in which 32 patients with RA-Br were matched for age (within 5 yr), sex and (where possible) disease duration with 32 patients with RA alone. An additional comparison group of 31 unselected patients with Br was chosen. All patients were followed for 5 yr. Patients with RA-Br were 7.3 times more likely to die than the general population, 5.0 times more likely than the RA group and 2.4 times more likely than the Br group. An increased risk of death within the RA-Br group was associated with a history of smoking, more severe RA and steroid usage. The co-existence of RA and Br is associated with a poor 5 yr survival.

Entities:  

Mesh:

Year:  1997        PMID: 9236680     DOI: 10.1093/rheumatology/36.6.689

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  17 in total

1.  Safety of immunomodulatory therapy in patients with bronchiectasis associated with rheumatic disease and IBD: a retrospective and cohort analysis.

Authors:  Pieter C Goeminne; Patrick Verschueren; Hans Scheers; Lieven J Dupont
Journal:  Clin Rheumatol       Date:  2011-09-22       Impact factor: 2.980

2.  Radiological and functional assessment of pulmonary involvement in the rheumatoid arthritis patients.

Authors:  Fikret Kanat; Funda Levendoglu; Turgut Teke
Journal:  Rheumatol Int       Date:  2007-03       Impact factor: 2.631

Review 3.  Prevalence and risk factors of bronchiectasis in rheumatoid arthritis: A systematic review and meta-analysis.

Authors:  Lily W Martin; Lauren C Prisco; Weixing Huang; Gregory McDermott; Nancy A Shadick; Tracy J Doyle; Jeffrey A Sparks
Journal:  Semin Arthritis Rheum       Date:  2021-08-20       Impact factor: 5.431

4.  Demographic, Lifestyle, and Serologic Risk Factors for Rheumatoid Arthritis (RA)-associated Bronchiectasis: Role of RA-related Autoantibodies.

Authors:  Gregory McDermott; Ritu Gill; Staci Gagne; Suzanne Byrne; Weixing Huang; Xiaosong Wang; Lauren C Prisco; Alessandra Zaccardelli; Lily W Martin; Lucy Masto; Vanessa L Kronzer; Nancy Shadick; Paul F Dellaripa; Tracy J Doyle; Jeffrey A Sparks
Journal:  J Rheumatol       Date:  2022-03-15       Impact factor: 5.346

5.  Inflammatory Markers in the Serum and Bronchoalveolar Lavage in Children with Non-Cystic Fibrosis Bronchiectasis.

Authors:  Hosseinali Ghaffaripour; Amir Rezaei; Maryam Hasanzad; Habib Emami; Esmaeil Mortaz; Alireza Mahdaviani; Ali Akbar Velayati
Journal:  Tanaffos       Date:  2021-04

Review 6.  Severe bronchiectasis.

Authors:  Brian M Morrissey; Samuel J Evans
Journal:  Clin Rev Allergy Immunol       Date:  2003-12       Impact factor: 8.667

7.  Computed tomography of pulmonary changes in rheumatoid arthritis: carcinoembryonic antigen (CEA) as a marker of airway disease.

Authors:  Milene Caroline Koch; Ivânio Alves Pereira; Luiz Felipe Souza Nobre; Fabricio Souza Neves
Journal:  Rheumatol Int       Date:  2016-02-17       Impact factor: 2.631

8.  Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis.

Authors:  David A Bergin; Killian Hurley; Adwait Mehta; Stephen Cox; Dorothy Ryan; Shane J O'Neill; Emer P Reeves; Noel G McElvaney
Journal:  J Inflamm Res       Date:  2013-01-23

Review 9.  Thoracic Manifestations of Rheumatoid Arthritis.

Authors:  Anthony J Esposito; Sarah G Chu; Rachna Madan; Tracy J Doyle; Paul F Dellaripa
Journal:  Clin Chest Med       Date:  2019-07-06       Impact factor: 4.967

10.  Chronic lung disease in U.S. Veterans with rheumatoid arthritis and the impact on survival.

Authors:  Bryant R England; Harlan Sayles; Kaleb Michaud; Geoffrey M Thiele; Jill A Poole; Liron Caplan; Brian C Sauer; Grant W Cannon; Andreas Reimold; Gail S Kerr; Joshua F Baker; Ted R Mikuls
Journal:  Clin Rheumatol       Date:  2018-10-02       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.